BeiGene Ltd (BGNE)
194.56
+0.30
(+0.15%)
USD |
NASDAQ |
Nov 21, 16:00
194.76
+0.20
(+0.10%)
After-Hours: 20:00
BeiGene Profit Margin (Quarterly): -12.12% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -12.12% |
| June 30, 2024 | -12.96% |
| March 31, 2024 | -33.41% |
| December 31, 2023 | -57.94% |
| September 30, 2023 | 27.57% |
| June 30, 2023 | -64.03% |
| March 31, 2023 | -77.81% |
| December 31, 2022 | -117.2% |
| September 30, 2022 | -143.8% |
| June 30, 2022 | -165.6% |
| March 31, 2022 | -141.9% |
| December 31, 2021 | -276.0% |
| September 30, 2021 | -212.2% |
| June 30, 2021 | -320.2% |
| March 31, 2021 | 10.98% |
| December 31, 2020 | -500.3% |
| September 30, 2020 | -466.9% |
| June 30, 2020 | -510.7% |
| March 31, 2020 | -698.7% |
| December 31, 2019 | -682.1% |
| September 30, 2019 | -613.0% |
| Date | Value |
|---|---|
| June 30, 2019 | -35.16% |
| March 31, 2019 | -215.4% |
| December 31, 2018 | -457.2% |
| September 30, 2018 | -265.7% |
| June 30, 2018 | -297.1% |
| March 31, 2018 | -321.4% |
| December 31, 2017 | -546.5% |
| September 30, 2017 | 53.31% |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | -6.14K% |
| March 31, 2016 | -3.25K% |
| December 31, 2015 | -582.6% |
| September 30, 2015 | -1.01K% |
| June 30, 2015 | -408.8% |
| March 31, 2015 | -740.5% |
| December 31, 2014 | -271.6% |
| September 30, 2014 | -150.2% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-698.7%
Minimum
Mar 2020
27.57%
Maximum
Sep 2023
-222.8%
Average
-142.9%
Median
Profit Margin (Quarterly) Benchmarks
| Theravance Biopharma Inc | -75.28% |
| Merck & Co Inc | 18.95% |
| Bristol-Myers Squibb Co | 10.18% |
| Zai Lab Ltd | -40.75% |
| Halozyme Therapeutics Inc | 47.23% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -24.64% |
| Return on Assets | -15.07% |
| Return on Invested Capital | -19.56% |
| Gross Profit Margin (Quarterly) | 82.98% |
| Operating Margin (Quarterly) | -12.01% |
| Return on Net Operating Assets | -32.56% |